Company news

Dare Bioscience, Inc. news in 2024

Dare Bioscience, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

December 15, 2024

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

December 9, 2024

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

December 3, 2024

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

November 13, 2024

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

November 12, 2024

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

November 6, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

October 22, 2024

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

October 20, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

August 25, 2024

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

August 12, 2024

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

August 11, 2024

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

August 4, 2024

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

July 18, 2024

Daré Bioscience Announces Reverse Stock Split

June 26, 2024

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

June 23, 2024

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 13, 2024

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

May 6, 2024

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 1, 2024

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

April 29, 2024

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

April 22, 2024

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

April 10, 2024

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

March 27, 2024

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

January 30, 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

January 25, 2024

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

January 16, 2024

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

January 3, 2024

Calls in 2024

Decks in 2024